Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

UGN-104 - Phase 3 | URGN Pipeline | CatalystAlert

UGN-104

Phase 3

UroGen Pharma Ltd. (URGN)

47%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Mar 31

URGN⭐Phase 3Phase 3

UGN-104 Phase 3 Results Expected

UGN-104 • Upper Urinary Tract Urothelial Carcinoma

Drug Information

Target Indication

Upper Urinary Tract Urothelial Carcinoma

Clinical Trial

Last updated: 12/4/2025

Developer

URGN

UroGen Pharma Ltd.

Biotechnology•North America•NASDAQ